212 related articles for article (PubMed ID: 8227490)
1. Effect of fluvoxamine on panic disorder.
Hoehn-Saric R; McLeod DR; Hipsley PA
J Clin Psychopharmacol; 1993 Oct; 13(5):321-6. PubMed ID: 8227490
[TBL] [Abstract][Full Text] [Related]
2. A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia.
Bakish D; Hooper CL; Filteau MJ; Charbonneau Y; Fraser G; West DL; Thibaudeau C; Raine D
Psychopharmacol Bull; 1996; 32(1):135-41. PubMed ID: 8927663
[TBL] [Abstract][Full Text] [Related]
3. An open trial of fluvoxamine therapy for panic disorder complicated by depression.
Spiegel DA; Saeed SA; Bruce TJ
J Clin Psychiatry; 1996; 57 Suppl 8():37-40; discussion 40-1. PubMed ID: 8698679
[TBL] [Abstract][Full Text] [Related]
4. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B
Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619
[TBL] [Abstract][Full Text] [Related]
5. Adinazolam sustained-release treatment of panic disorder: a double-blind study.
Davidson JR; Beitman B; Greist JH; Maddock RJ; Lewis CP; Sheridan AQ; Carter C; Krishnan KR; Liebowitz MR; Haack DG
J Clin Psychopharmacol; 1994 Aug; 14(4):255-63. PubMed ID: 7962681
[TBL] [Abstract][Full Text] [Related]
6. Adinazolam-SR in panic disorder with agoraphobia: relationship of daily dose to efficacy.
Carter CS; Fawcett J; Hertzman M; Papp LA; Jones W; Patterson WM; Swinson RP; Weise CC; Maddock RJ; Denahan AQ
J Clin Psychiatry; 1995 May; 56(5):202-10. PubMed ID: 7737960
[TBL] [Abstract][Full Text] [Related]
7. A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder.
Lydiard RB; Lesser IM; Ballenger JC; Rubin RT; Laraia M; DuPont R
J Clin Psychopharmacol; 1992 Apr; 12(2):96-103. PubMed ID: 1573046
[TBL] [Abstract][Full Text] [Related]
8. Serotonin, panic disorder and agoraphobia: short-term and long-term efficacy of citalopram in panic disorders.
Humble M; Wistedt B
Int Clin Psychopharmacol; 1992 Jun; 6 Suppl 5():21-39. PubMed ID: 1431019
[TBL] [Abstract][Full Text] [Related]
9. Clinical effects of fluvoxamine on panic symptomatology.
Pols H; Zandergen J; de Loof C; Fernandez I; Griez E
Acta Psychiatr Belg; 1993; 93(3):169-77. PubMed ID: 8030430
[TBL] [Abstract][Full Text] [Related]
10. Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety.
Sheehan DV; McElroy SL; Harnett-Sheehan K; Keck PE; Janavs J; Rogers J; Gonzalez R; Shivakumar G; Suppes T
J Affect Disord; 2009 Jun; 115(3):376-85. PubMed ID: 19042026
[TBL] [Abstract][Full Text] [Related]
11. Double-blind comparison of 30 and 60 mg tranylcypromine daily in patients with panic disorder comorbid with social anxiety disorder.
Nardi AE; Lopes FL; Valença AM; Freire RC; Nascimento I; Veras AB; Mezzasalma MA; de-Melo-Neto VL; Soares-Filho GL; King AL; Grivet LO; Rassi A; Versiani M
Psychiatry Res; 2010 Feb; 175(3):260-5. PubMed ID: 20036427
[TBL] [Abstract][Full Text] [Related]
12. Alpidem in the treatment of panic disorder.
Schneier FR; Carrasco JL; Hollander E; Campeas R; Fallon B; Saoud JB; Feerick J; Liebowitz MR
J Clin Psychopharmacol; 1993 Apr; 13(2):150-3. PubMed ID: 8096527
[TBL] [Abstract][Full Text] [Related]
13. Clonazepam in the treatment of panic disorder: a double-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response.
Beauclair L; Fontaine R; Annable L; Holobow N; Chouinard G
J Clin Psychopharmacol; 1994 Apr; 14(2):111-8. PubMed ID: 8195451
[TBL] [Abstract][Full Text] [Related]
14. Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks.
Munjack DJ; Crocker B; Cabe D; Brown R; Usigli R; Zulueta A; McManus M; McDowell D; Palmer R; Leonard M
J Clin Psychopharmacol; 1989 Feb; 9(1):22-7. PubMed ID: 2651490
[TBL] [Abstract][Full Text] [Related]
15. An open-label trial of nefazodone in high comorbidity panic disorder.
DeMartinis NA; Schweizer E; Rickels K
J Clin Psychiatry; 1996 Jun; 57(6):245-8. PubMed ID: 8666561
[TBL] [Abstract][Full Text] [Related]
16. Issues in the assessment of treatment response in panic disorder with special reference to fluvoxamine.
Ninan PT
J Clin Psychiatry; 1997; 58 Suppl 5():24-31. PubMed ID: 9184624
[TBL] [Abstract][Full Text] [Related]
17. The use of the Panic and Agoraphobia Scale (P & A) in a controlled clinical trial.
Bandelow B; Broocks A; Pekrun G; George A; Meyer T; Pralle L; Bartmann U; Hillmer-Vogel U; Rüther E
Pharmacopsychiatry; 2000 Sep; 33(5):174-81. PubMed ID: 11071019
[TBL] [Abstract][Full Text] [Related]
18. A controlled study of alprazolam and propranolol in panic-disordered and agoraphobic outpatients.
Ravaris CL; Friedman MJ; Hauri PJ; McHugo GJ
J Clin Psychopharmacol; 1991 Dec; 11(6):344-50. PubMed ID: 1770152
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
Arnold LM; Lu Y; Crofford LJ; Wohlreich M; Detke MJ; Iyengar S; Goldstein DJ
Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467
[TBL] [Abstract][Full Text] [Related]
20. [Obsessive-compulsive symptoms associated with panic disorder. Predictive factor of a good therapeutic response to fluvoxamine].
Servant D; Bailly D; Le Seac'h H; Parquet PJ
Encephale; 1990; 16 Spec No():359-62. PubMed ID: 2120029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
